Hormonal
Higher baseline levels of Interleukin-6 (IL-6) and a steeper longitudinal increase in IL-6 levels are independently associated with an accelerated rate of developing multimorbidity (accumulation of chronic diseases) in older adults.
If you are over 60, monitoring inflammatory markers like IL-6 may help predict your risk of developing multiple chronic conditions. High or rising IL-6 levels are linked to a faster accumulation of diseases. This suggests that managing inflammation could be a key strategy to slow down the progression of multimorbidity in older adults.
higher baseline IL-6 and steeper increase of IL-6 levels were significantly and independently associated with a steeper increase in multimorbidity over time (p < .001 and p = .003, respectively).
Why this rating
Longitudinal study with 9-year follow-up and large sample size (n=1018), though observational design limits causal inference.
Source
Aging and the Burden of Multimorbidity: Associations With Inflammatory and Anabolic Hormonal Biomarkers
Elisa Fabbri et al. · The Journals of Gerontology Series A · 2014
DOI 10.1093/gerona/glu127
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →